Search Results
Sep 03, 2026, 08:30 ET Microland Foundation Supports Project SHOLA to Restore Upper Nilgiris Wetlands and Empower Community-Led Conservation
move beyond immediate challenges towards a more equitable, resilient, and opportunity-rich future.About EBR Center TrustThe Edhkwehlynawd Botanical Refuge (EBR) Centre Trust is a dedicated organization established to address the urgent need for both ecological restoration and
More news about: Microland Foundation
Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Aug 31, 2026, 07:00 ET RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Aug 31, 2026, 07:00 ET RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Jul 28, 2026, 07:00 ET Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Jun 22, 2026, 16:10 ET RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Jun 18, 2026, 08:00 ET RedHill Biopharma Announces Up To $19.4 Million Private Placement
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Jun 16, 2026, 08:00 ET Gryphon AI Joins Google Cloud Marketplace to Operationalize Agentic Governance for Human and AI-Driven Outreach
platform enforces complex business-specific policies, including contact frequency limits, time-of-day restrictions, and established business relationship (EBR) rules.Drive Operational Velocity: By automating real-time certification, organizations can eliminate manual compliance reviews and fragmented
More news about: Gryphon AI
Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Jun 08, 2026, 07:00 ET RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Jun 02, 2026, 08:00 ET RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Apr 30, 2026, 07:00 ET RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104,
More news about: RedHill Biopharma Ltd.
Apr 15, 2026, 07:31 ET First American Nuclear Submits Regulatory Engagement Plan for Fast-Spectrum Small Modular Reactor (SMR)
nearly every major fast-reactor program in the Western Hemisphere, including the Fast Flux Test Facility (FFTF), Experimental Breeder Reactor II (EBR-II), Versatile Test Reactor (VTR), Fuels and Materials Examination Facility (FMEF), and the Global Nuclear Energy Partnership (GNEP).Factory-Built,
More news about: First American Nuclear Co.
Mar 30, 2026, 01:33 ET WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
faster timelines, superior quality, and full partnership transparency. By leveraging digital manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain, consistent data integrity and high product quality, while its advanced planning systems
More news about: WuXi Biologics
Mar 24, 2026, 07:44 ET WuXi Biologics Reports Record 2025 Annual Results
collaboration, while core lab management system, together with in-silico modeling, and intelligent manufacturing systems such as Electronic Batch Records (EBR), Manufacturing Execution System (MES) enhance productivity, efficiency and quality. In addition, PatroLab™, the Group's digital twin platform, supports
More news about: WuXi Biologics
Mar 12, 2026, 23:09 ET WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
faster timelines, superior quality, and full partnership transparency. By leveraging digital manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and consistent data integrity and high product quality, while its advanced planning systems
More news about: WuXi Biologics
Mar 06, 2026, 08:00 ET Valcare Medical Appoints Two New Members to Board of Directors
structural heart technologies. His career includes progressively senior roles at Boston Scientific, Medtronic, Direct Flow Medical, Keystone Heart, and EBR Systems, where he most recently served as General Manager and Chief Commercial Officer, respectively.About the AMEND TS Early Feasibility StudyThe
More news about: Valcare Medical
Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences
study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease
More news about: RedHill Biopharma Ltd.
Feb 19, 2026, 09:00 ET PossibleNOW Launches First Major 2026 DNCSolution Release with Reimagined Bulk Scrubbing and Centralized EBR Policy Management
into the bulk scrubbing workflow, eliminating manual steps and improving compliance accuracy.Enhanced Established Business Relationship (EBR) Policy Management – A streamlined configuration experience that makes rule management clearer and more flexible.RND Usage Reporting
More news about: PossibleNOW
Feb 17, 2026, 17:31 ET Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
to around 173K by 2036.Leading juvenile idiopathic arthritis companies, such as Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN), and others, are developing new juvenile idiopathic arthritis treatment drugs that can be available in the juvenile idiopathic
More news about: DelveInsight Business Research, LLP
Jan 21, 2026, 06:00 ET InstantGMP Named #1 for EBR Integration in LIMS and MES Supporting Paperless Manufacturing
Electronic Batch Record (EBR) integration within both Laboratory Information Management Systems (LIMS) and Manufacturing Execution Systems (MES) to support fully paperless
More news about: InstantGMP, Inc.
Jan 14, 2026, 23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
enabling digital twins, in‑silico modeling and predictive decision-making. By leveraging smart manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and ensured data integrity and high product quality, while advanced planning systems
More news about: WuXi Biologics
Jan 05, 2026, 07:00 ET RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease
More news about: RedHill Biopharma Ltd.